Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0163 | 0.5383 | 1 |
Echinococcus granulosus | cathepsin b | 0.0163 | 0.5383 | 0.5 |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.0156 | 0.4995 | 1 |
Toxoplasma gondii | cathepsin CPC1 | 0.0156 | 0.4995 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0163 | 0.5383 | 1 |
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.0156 | 0.4995 | 1 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0163 | 0.5383 | 0.5 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0156 | 0.4995 | 0.4995 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.0156 | 0.4995 | 1 |
Echinococcus granulosus | cathepsin b | 0.0163 | 0.5383 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.0163 | 0.5383 | 0.5 |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.0156 | 0.4995 | 1 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0163 | 0.5383 | 1 |
Echinococcus multilocularis | cathepsin b | 0.0163 | 0.5383 | 0.5 |
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.0156 | 0.4995 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0163 | 0.5383 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 25 uM | Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation | ChEMBL. | 26001344 |
IC50 (functional) | = 85 uM | Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation | ChEMBL. | 26001344 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.